Recurrent neurosurgical site infection by extensively drug-resistant P. aeruginosa treated with cefiderocol: a case report and literature review.
- Authors
- Type
- Published Article
- Journal
- Infectious diseases (London, England)
- Publication Date
- Mar 01, 2021
- Volume
- 53
- Issue
- 3
- Pages
- 206–211
- Identifiers
- DOI: 10.1080/23744235.2020.1856921
- PMID: 33295821
- Source
- Medline
- Keywords
- Language
- English
- License
- Unknown
Abstract
Cefiderocol is a new siderophore cephalosporin designed to be active against extensively resistant Gram-negative bacteria; however, clinical studies are limited to complicated urinary tract infections, pneumonia, and intra-abdominal infections. To date, no data are available on neurosurgical site infections. We present a case of a patient successfully cured with Cefiderocol for a neurosurgical site infection due to extensively resistant P. aeruginosa, who had failed a previous treatment based on combined antimicrobial therapy and right parietal bone excision. Cefiderocol is a promising antibiotic for complicated infections due to multidrug resistant gram-negative bacteria.
